<DOC>
	<DOCNO>NCT01061034</DOCNO>
	<brief_summary>Aspirin weak acid cross gastric intestinal mucosa passive diffusion lipophilic nature.Omeprazole , proton pump inhibitor , inhibit gastric acid secretion . We assume omeprazole inhibits aspirin absorption , thus reduce action platelet . healthy volunteer , know peptic disease bleed disorder enrol . All volunteer receive 7 day Aspirin ( 100mg ) alone , follow 14 day Aspirin Omeprazole 20mg twice daily 3 day 20mg daily . Blood level Aspirin determine High performance liquid chromatography ( HPLC ) , 0 , 1 , 2 , 4 , 6 , 10 , 24 hour administration Aspirin alone day 7 Aspirin plus Omeprazole day 21 . Platelet function test determine platelet-rich plasma aggregometry response Arachidonic acid ( 500mg/ml ) , Ristocetin ( 1.5mg/ml ) Adenosine 5'-diphosphate ( 20mM ) day 0 baseline day 7 21 study .</brief_summary>
	<brief_title>Pharmacological Study That Measures Omeprazole Effect Aspirins Absorption Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>healthy volunteer pretreatment aspirin pretreatment non steroidal anti inflamatory drug pretreatment antacid history peptic ulcer disease coagulation aggregation disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>aspirin</keyword>
	<keyword>proton pump inhiditor</keyword>
</DOC>